NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT05145816 2026-02-17
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT05002816 2025-10-30
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
Phase 1/2 Recruiting
NCT04896658 2025-04-03
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT05853965 2025-03-30
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Recruiting
NCT04808037 2023-10-24
BelaRd
Hellenic Society of Hematology
Phase 1/2 Active not recruiting
NCT05493618 2023-01-27
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT05060627 2022-09-08
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
Phase 1/2 Recruiting